Tessenderlo Group NV (TSDOF) Q2 2026 Earnings Call Transcript

Tessenderlo Group discussed its H1 2026 results while highlighting a new joint venture: a definitive agreement with Darling Ingredients (set in Dec 2025) to build a collagen-based health, wellness and nutrition products company. In the JV, Tessenderlo holds 15% and Darling holds 85%, with Tessenderlo also retaining a Board presence. Management framed the first half as “turbulent” amid global disruptions (including the Strait of Hormuz) but did not provide specific financial figures in the excerpt.

Analysis

The market should treat this as a strategic optionality event, not an earnings step-up. DAR is the economic winner because it controls the platform and can fold a higher-multiple nutrition asset into a broader portfolio, but the equity story only improves if the JV proves it can source feedstock cheaply and scale without heavy working-capital drag. For TSDOF, the 15% stake is more about monetization and hidden asset value than near-term EPS; that usually supports the stock only if investors start assigning a separate value to the stake rather than capitalizing it at zero.

The second-order dynamic is supply-chain leverage: collagen is a traceability business as much as a demand business, so integrated players with rendering/byproduct access have an edge over smaller stand-alone processors. That can squeeze mid-tier competitors on input security before it affects final pricing. The real loser, if this works, is not a specific named peer today but any ingredient company that lacks vertical control and has to buy feedstock at spot-like terms.

Risk is timing. These collaborations typically take 12-24 months before they move reported EBITDA, and the market can lose patience well before that. What would falsify the thesis is any sign that the JV needs incremental capital, misses customer qualification milestones, or fails to disclose a credible margin bridge by FY27; absent that, the stock reaction should stay muted rather than rerate aggressively.

Contrarian view: the consensus may be overestimating how quickly collagen growth translates into equity value. Without disclosure on capacity, capex, and customer concentration, this could be a nice strategic headline with little observable financial impact for several quarters.

Key Decisions for Investors

• No immediate directional trade: treat DAR/TSDOF as a watch item until the JV discloses capital intensity, margin target, and launch timing; the current signal is too small for a high-conviction position.
• If DAR weakens 3-5% on the call, buy the dip for a 1-3 month mean-reversion trade; catalyst is incremental JV detail and potential re-rating toward higher-multiple nutrition exposure.
• Use TSDOF only as a hidden-asset watchlist long: initiate only if management confirms the stake is non-dilutive and ring-fenced; exit if the JV requires follow-on funding or no customer ramp appears by FY27.
• Do not short the broader ingredients basket on this news; the competitive impact is likely more about vertical integration and sourcing advantage than near-term share loss.
• Set an alert for any disclosure of JV EBITDA, capex, or working-capital assumptions; those metrics will determine whether the market assigns value or keeps treating this as a non-event.